Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎, New York, NY 10065
(646) 856-9261
[email protected]

Robert W. Busby

Head of Clinical Pharmacology/ DMPK

Robert W. Busby, Ph.D. is an accomplished scientific and organizational leader with 25 years of pharmaceutical R&D experience. He was previously Vice President of Analytical Pharmacology/DMPK/Clinical Pharmacology at Ironwood Pharmaceuticals. At Ironwood, Dr. Busby played a critical role in bringing Linzess (linaclotide) to patients, and was part of that drug development program from early discovery through approval and launch. In his 15 years at Ironwood (formerly Microbia), he led the initial effort to build essential drug discovery capabilities and helped the company make the transition from start-up to a successful public company. Dr. Busby established and led multiple departments covering a broad range of scientific disciplines and contributing at all stages of drug discovery and development. Prior to Ironwood, he worked at SmithKline Beecham (now GSK) and also DuPont. Dr. Busby holds a Ph.D. in Bioorganic Chemistry from The Johns Hopkins University and a BS in Chemistry from Drexel University.